We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 29, 2021

Renoprotective Effects of Empagliflozin Plus Liraglutide vs Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease

Diabetes Care


Additional Info

Diabetes Care
Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
Diabetes Care 2021 Aug 06;[EPub Ahead of Print], RV Cohen, TBZ Petry, AD Miras, CM Aboud, B Johnson, TM Dos Santos, CW le Roux

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading